| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advances in the treatment of metabolic diseases
|
DiMarchi, Richard D.
|
|
|
46 |
C |
p.
|
article
|
| 2 |
“A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes”
|
Gupta, Deepali
|
|
|
46 |
C |
p.
|
article
|
| 3 |
Editorial Board, cover figure description and credits
|
|
|
|
46 |
C |
p.
|
article
|
| 4 |
FGF19 and FGF21: In NASH we trust
|
Talukdar, Saswata
|
|
|
46 |
C |
p.
|
article
|
| 5 |
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
|
Nauck, Michael A.
|
|
|
46 |
C |
p.
|
article
|
| 6 |
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
|
Baggio, Laurie L.
|
|
|
46 |
C |
p.
|
article
|
| 7 |
Growth differentiation factor 15 as a potential therapeutic for treating obesity
|
Hale, Clarence
|
|
|
46 |
C |
p.
|
article
|
| 8 |
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
|
Sonne, Nina
|
|
|
46 |
C |
p.
|
article
|
| 9 |
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
|
Finan, Brian
|
|
|
46 |
C |
p.
|
article
|
| 10 |
Review: Glucose-sensitive insulin
|
Hoeg-Jensen, Thomas
|
|
|
46 |
C |
p.
|
article
|
| 11 |
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
|
Campbell, Jonathan E.
|
|
|
46 |
C |
p.
|
article
|
| 12 |
The gut–brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders
|
Richards, Paul
|
|
|
46 |
C |
p.
|
article
|
| 13 |
Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
|
Goedeke, Leigh
|
|
|
46 |
C |
p.
|
article
|
| 14 |
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
|
Veelen, Anna
|
|
|
46 |
C |
p.
|
article
|
Journal description